L2Capital Deep research, on demand
Login Register
ISRG logo

ISRG · Intuitive Surgical, Inc.

Last updated Nov 03, 2026
Recommendation
BUY
12-Month Target
$505.00
+15.6% return
Reference Price
$436.87
November 03, 2026
Download PDF Read HTML
INSTITUTIONAL MEMORANDUM · ISRG NASDAQ 100

Has the monopoly already died?

Competition is real, but procedure growth, recurring revenue and buybacks say the moat still compounds.

L2 Capital Institutional Verdict

Intuitive Surgical, Inc. (ISRG) is currently rated BUY with a 12-month valuation target of $505.00 (implied return: +15.6%). Based on forensic analysis of SEC filings and audited cash flows, Medium-High conviction reflects Q3 revenue grew 22%, while da Vinci and Ion procedures expanded 14% and 31%, respectively..

Executive Thesis

BUY reflects a rare opportunity to acquire a structurally advantaged medical-technology compounder below its recent historical valuation range. The installed-base flywheel, procedure-linked consumables, da Vinci 5 migration and international penetration support durable mid-teens earnings growth. Competition, recurring stock compensation and antitrust remedies are material—not cosmetic—but current operating evidence does not indicate franchise impairment. Initiate or add below $440, with a $505 twelve-month target and disciplined sizing given multiple risk.

Key Actionable Findings

Click any finding to interrogate with Andy ↗
Q3 revenue grew 22%, while da Vinci and Ion procedures expanded 14% and 31%, respectively.
Approximately 84% of Q3 revenue was recurring, supported by 12,094 da Vinci and 1,152 Ion systems.
The $450 million antitrust settlement removes a major overhang but leaves injunctive-remedy and aftermarket risks.

Frequently Asked Questions: ISRG

What is L2 Capital's investment rating and price target for ISRG?

L2 Capital currently maintains an institutional rating of BUY on Intuitive Surgical, Inc. (ISRG) with a 12-month target price of $505.00 (implied return: +15.6%), backed by Medium-High conviction.

What is the core investment thesis for ISRG?

BUY reflects a rare opportunity to acquire a structurally advantaged medical-technology compounder below its recent historical valuation range. The installed-base flywheel, procedure-linked consumables, da Vinci 5 migration and international penetration support durable mid-teens earnings growth. Competition, recurring stock compensation and antitrust remedies are material—not cosmetic—but current operating evidence does not indicate franchise impairment. Initiate or add below $440, with a $505 twelve-month target and disciplined sizing given multiple risk.

What are ISRG's latest audited financial fundamentals?

According to audited SEC EDGAR filings, Intuitive Surgical, Inc. reported total revenue of $10.06B (+20.5% YoY), Gross Margin of 66.0%, Free Cash Flow of N/A, and Net Debt of -$3.37B.

What key risks and catalyst factors should investors monitor for ISRG?
  • Q3 revenue grew 22%, while da Vinci and Ion procedures expanded 14% and 31%, respectively.
  • Approximately 84% of Q3 revenue was recurring, supported by 12,094 da Vinci and 1,152 Ion systems.
  • The $450 million antitrust settlement removes a major overhang but leaves injunctive-remedy and aftermarket risks.